XHXinxin Huang

Xinxin Huang

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Xinxin Huang has a total of 34 co-authors. Here are the top co-authors by number of shared publications:

  • Xiaojian Wu

    Department of General Surgery (Colorectal Surgery), The Sixth Affiliated Hospital, Sun Yat-sen University, Guangzhou, China

    4 shared publications
  • Peishan Hu

    Department of General Surgery (Department of Colorectal Surgery), The Sixth Affiliated Hospital, Sun Yat-sen University, Guangzhou, China; Guangdong Provincial Key Laboratory of Colorectal and Pelvic Floor Diseases, The Sixth Affiliated Hospital, Sun Yat-sen University, Guangzhou, China; Biomedical Innovation Center, The Sixth Affiliated Hospital, Sun Yat-sen University, Guangzhou, China; Guangdong Provincial Clinical Research Center for Digestive Diseases, Guangzhou, Guangdong, China

    3 shared publications
  • Chong Chen

    Department of General Surgery (Colorectal Surgery), The Sixth Affiliated Hospital of Sun Yat-Sen University, Sun Yat-Sen University, Guangzhou 510630, China

    2 shared publications
  • Dongwen Chen

    Department of General Surgery (Colorectal Surgery), The Sixth Affiliated Hospital of Sun Yat-Sen University, Sun Yat-Sen University, Guangzhou 510630, China

    2 shared publications
  • Huaiqiang Ju

    Sun Yat-Sen University Cancer Center, State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University, Guangzhou 510220, China

    2 shared publications
  • Xiaotong Luo

    Innovation Center of the Sixth Affiliated Hospital, School of Life Sciences, Sun Yat-Sen University, Guangzhou, 510060, China.

    2 shared publications

Latest Publications

  • Open Access

    Light Exposure Ameliorates Tau-Induced Deficits via Adenosine Signaling and Mitochondrial Quality Control in Drosophila

    by Su Zhang, Yuanhang Xiang, Xinxin Huang, Chuncao Ao, Linfeng Chen, Xinhui Zhang, Zhong Li

    Background: Accumulating evidence suggests that environmental light cues influence brain function and neurodegenerative processes; however, the underlying cellular mechanisms remain incompletely understood. Methods: Here, using a Tau-overexpressing Drosophila model, we investigated how light exposure modulates neurodegeneration-associated phenotypes, with a particular focus on adenosine signaling and mitochondrial homeostasis. We performed behavioral assays, biochemical measurements, genetic interference targeting the adenosine receptor, and mito-QC reporter analysis to assess mitochondrial quality control. Results: We show that light exposure ameliorates Tau-induced behavioral impairments and neuropathological features, reducing climbing time by approximately 29% in males and 45% in females, and extending median lifespan by ~29% in males and ~26% in females. Notably, biochemical analyses revealed that light exposure significantly increases brain adenosine levels at ZT12 by approximately 5 to 6 nmol/L in both sexes (p < 0.01), suggesting a light-dependent modulation of adenosine availability. To further examine the role of adenosine signaling, we performed genetic interference experiments targeting the adenosine receptor. These results indicate that adenosine receptor-associated signaling is functionally involved in the beneficial effects of light, as disruption of this pathway attenuates the light-induced improvements in behavioral and mitochondrial phenotypes. Using a mito-QC reporter system, we further show that light exposure enhances mitochondrial quality control, as reflected by a ~2.3-fold increase in mitolysosome density (p < 0.001). Importantly, this effect is modulated by the functional state of adenosine signaling, suggesting a potential interaction between these processes. Conclusions: Together, our findings indicate that light exposure is associated with coordinated changes in adenosine signaling and mitochondrial quality control, which may contribute to the attenuation of Tau-induced deficits in Drosophila. This work provides insight into how environmental light cues may influence neurodegeneration-related cellular processes and highlights the potential relevance of light-based interventions for future mechanistic and translational studies.

  • Open Access

    Correction: Huang et al. Duodenal Adenocarcinoma Is Characterized by Acidity, High Infiltration of Macrophage, and Activated Linc01559–GRSF1 Axis. Biomedicines 2025, 13, 1611

    by Xinxin Huang, Ying Shi, Zekun Liu, Yihang Wu, Xiaotong Luo, Dongwen Chen, Zhengyu Wei, Chong Chen, Huaiqiang Ju, Xiaojian Wu, et al.


  • Open Access

    Duodenal Adenocarcinoma Is Characterized by Acidity, High Infiltration of Macrophage, and Activated Linc01559–GRSF1 Axis

    by Xinxin Huang, Ying Shi, Zekun Liu, Yihang Wu, Xiaotong Luo, Dongwen Chen, Zhengyu Wei, Chong Chen, Huaiqiang Ju, Xiaojian Wu, et al.

    Background: Duodenal adenocarcinoma (DA) is often insidious due to the low rate of early diagnosis and because the mechanisms that underlie its malignant progression are poorly understood. The tumor microenvironment (TME) plays a crucial regulatory role in promoting tumor malignancy. Hence, this study aimed to identify novel biomarkers for early diagnosis and potential therapeutic targets for DA. Methods: Surgical resection samples and normal tissues from DA patients were collected for RNA sequencing (RNA-seq). The characteristics of TME in DA patients were analyzed, and the differentially expressed long non-coding RNAs (lncRNA) were screened. Functional experiments were performed to verify the relationship between Linc01559, G-rich sequence binding factor 1 (GRSF1), and tumor malignant phenotype. Results: The present study revealed that DA exhibits a significantly upregulated expression of acidic environment markers and a high degree of macrophage infiltration. Further investigation revealed that macrophages upregulate the expression of the long noncoding RNA, Linc01559, in DA through the STAT3/c-MYC signaling pathway, thereby promoting malignant phenotypes such as invasion, metastasis, tumor stemness, and apoptosis. The interaction between GRSF1 and Linc01559 was subsequently confirmed using RNA pulldown-mass spectrometry. It was further revealed that Linc01559 promotes the malignant phenotype of duodenal cancer cells through its interaction with GRSF1. Conclusions: These findings demonstrate that the acidic microenvironment influences the phenotype of DA by regulating the Linc01559–GRSF1 axis. Therefore, these findings provide potential targets for the early detection and treatment of DA.


  • Open Access

    Tumor-intrinsic TTLL12 drives resistance to cancer immunotherapy via modulating myeloid-derived suppressor cells

    by Dong-Wen Chen, Yi-Kan Cheng, Pei-Si Li, Xiao-Jian Wu, Xin-Xin Huang, Jia-Hui Long, Zhizhong Xiong, Chong Chen, Shu-Biao Ye, Ping Lan

    Background: The majority of patients treated with immunotherapy as a standalone therapy experience little to no benefits. Tubulin tyrosine ligase 12 (TTLL12), as a member of the tubulin tyrosine ligase protein family, is associated with the prognosis of patients with cancer and implicated in regulating innate immunity. However, the role of TTLL12 in modulating antitumor immunity remains unclear. Methods: We analyzed the expression of TTLL12 in several cancer types and evaluated the putative correlation between TTLL12 expression and the immune infiltration in our own proteomic profile of human colorectal cancer. The gain-of-function or loss-of-function approaches were then implemented in vitro and in vivo, followed by flow cytometry to quantify immune cell population frequency. In vitro assays were used to confirm the influence of TTLL12 on the migration and proliferation of the immune subset. Mass spectrometry and chromatin-immunoprecipitation were used to further explore how TTLL12 influenced the immune subset. Finally, whether TTLL12 could enhance the antitumor efficacy of anti-programmed cell death protein 1 (PD-1) therapy was assessed in an immunocompetent mouse model. Results: We demonstrated that TTLL12 was upregulated in several cancer types and was linked with poor prognosis in patients with colorectal cancer. TTLL12 was found to be negatively correlated with the immune effector signature on the protein level in our proteomic datasets. TTLL12 ectopic expression in tumor cells did not influence cell proliferation but promoted tumor progression in syngeneic mouse models by modulating myeloid-derived suppressor cells (MDSCs), resulting in a suppressive immune response. TTLL12 was further proved to enrich MDSCs by promoting MDSC migration and proliferation in vitro. Mechanistically, tumor-derived TTLL12 induced the secretion of chemokine CCL9 via promoting its transcription, probably through binding to the promoter region of CCL9. Downregulating TTLL12 could significantly improve the efficacy of anti-PD-1 therapy in an immunocompetent murine model. Conclusion: We identify TTLL12 as a key determinant of suppressive immune response, highlighting a previously unknown therapeutic target to increase the efficacy of antitumor immunotherapy.


  • Open Access

    KRAS Inhibitors Are Potential Prophylaxis for Colorectal Cancer Metachronous Metastasis

    by Yaoyu Guo, Chuling Hu, Guojie Long, Du Cai, Zhaoliang Yu, Xingxing Huang, Zerong Cai, Peishan Hu, Yufeng Chen, Feng Gao, et al.

    Colorectal cancer (CRC) with KRAS mutation is prone to develop metachronous metastasis. However, effective measures for prediction and prevention of such clinical issue are currently unavailable. In this study, we confirmed that KRAS mutation is a risk factor for CRC metachronous metastasis through meta-analysis and public database analysis. Based on the ICGC-AGRO database, we have constructed a risk scoring model for predicting metachronous metastasis in KRAS-mutant CRC using machine learning, which was validated in public datasets. Furthermore, we discovered that KRAS inhibitors can effectively suppress the migration and invasion capabilities of high risk CRC cells by wound healing assay and transwell experiment, which was validated ex vivo and in vivo using organoids and splenic liver metastatic mouse model. Finally, RNA sequencing, RT-qPCR, and western blots have proven that KRAS inhibitors can suppress the epithelial-mesenchymal transition (EMT) and transforming growth factor beta (TGF-beta) signaling pathway in CRC. Collectively, our study suggests that KRAS inhibitors may inhibit the metastatic ability of CRC by suppressing EMT and the TGF-beta pathway, suggesting their potential for the prevention of metachronous metastasis in CRC with KRAS mutation.